Total Payments
$2.8M
2024 Payments
$608,974
Companies
42
Transactions
2,167
Medicare Patients
5,010
Medicare Billing
$1.4M
Payment Breakdown by Category
Other$2.1M (73.4%)
Travel$387,376 (13.8%)
Consulting$294,405 (10.5%)
Food & Beverage$34,565 (1.2%)
Research$28,421 (1.0%)
Education$1,822 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.8M | 568 | 63.5% |
| Travel and Lodging | $387,376 | 733 | 13.8% |
| Consulting Fee | $294,405 | 105 | 10.5% |
| Honoraria | $235,320 | 117 | 8.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $41,815 | 17 | 1.5% |
| Food and Beverage | $34,565 | 618 | 1.2% |
| Unspecified | $28,421 | 3 | 1.0% |
| Education | $1,822 | 6 | 0.1% |
Payments by Type
General
$2.8M
2,164 transactions
Research
$28,421
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $513,687 | 274 | $0 (2024) |
| Celgene Corporation | $369,078 | 296 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $295,263 | 282 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $229,133 | 122 | $0 (2024) |
| Blueprint Medicines Corporation | $205,900 | 207 | $0 (2024) |
| GlaxoSmithKline, LLC. | $149,683 | 74 | $0 (2024) |
| PharmaEssentia USA Corporation | $144,532 | 96 | $0 (2024) |
| Amgen Inc. | $136,470 | 132 | $0 (2024) |
| Incyte Corporation | $120,483 | 97 | $0 (2024) |
| Stemline Therapeutics Inc. | $108,435 | 81 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $608,974 | 425 | GlaxoSmithKline, LLC. ($132,147) |
| 2023 | $426,468 | 307 | PharmaEssentia USA Corporation ($93,108) |
| 2022 | $383,379 | 268 | E.R. Squibb & Sons, L.L.C. ($107,769) |
| 2021 | $197,279 | 148 | Celgene Corporation ($50,617) |
| 2020 | $249,421 | 150 | Celgene Corporation ($84,601) |
| 2019 | $354,702 | 310 | Takeda Pharmaceuticals U.S.A., Inc. ($97,784) |
| 2018 | $327,680 | 305 | Takeda Pharmaceuticals U.S.A., Inc. ($110,760) |
| 2017 | $256,101 | 254 | Celgene Corporation ($94,281) |
All Payment Transactions
2,167 individual payment records from CMS Open Payments — Page 1 of 87
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Geron Corporation | RYTELO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/20/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $17.86 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/20/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $1.60 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/16/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,350.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,340.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | SOBI, INC | VONJO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,080.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/12/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Travel and Lodging | Cash or cash equivalent | $147.90 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,350.00 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Geron Corporation | RYTELO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/11/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $17.60 | General |
| Category: Hematology/Oncology | ||||||
| 12/05/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Travel and Lodging | In-kind items and services | $793.65 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $218.04 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/05/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $143.46 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Geron Corporation | RYTELO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,600.00 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,400.00 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $3,276.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,008.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,008.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $1,008.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Travel and Lodging | Cash or cash equivalent | $531.26 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/03/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Honoraria | Cash or cash equivalent | $504.00 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Travel and Lodging | In-kind items and services | $690.91 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LAM 003-HEM-CLN02 | AI Therapeutics, Inc. | $15,053 | 1 |
| LAM-003-HEM-CLN02 | AI Therapeutics, Inc. | $13,368 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 858 | 8,800 | $797,441 | $262,311 |
| 2022 | 13 | 1,269 | 9,514 | $708,554 | $292,471 |
| 2021 | 15 | 1,447 | 12,233 | $929,329 | $424,333 |
| 2020 | 14 | 1,436 | 14,909 | $1.0M | $434,224 |
Total Patients
5,010
Total Services
45,456
Medicare Billing
$1.4M
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 221 | 493 | $148,231 | $72,200 | 48.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 173 | 458 | $109,294 | $48,955 | 44.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 473 | $102,856 | $48,065 | 46.7% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 34 | 6,680 | $272,200 | $38,891 | 14.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 111 | 243 | $37,336 | $17,910 | 48.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 43 | 67 | $28,144 | $9,931 | 35.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 37 | 37 | $16,796 | $6,737 | 40.1% |
| 85097 | Bone marrow, smear interpretation | Office | 2023 | 39 | 60 | $19,940 | $3,650 | 18.3% |
| 38221 | Biopsy of bone marrow | Office | 2023 | 21 | 23 | $14,357 | $3,380 | 23.5% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 20 | 20 | $8,861 | $2,866 | 32.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 40 | $6,196 | $2,706 | 43.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 23 | 33 | $5,653 | $2,296 | 40.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 36 | 137 | $10,419 | $1,651 | 15.8% |
| 38220 | Aspiration of bone marrow sample for diagnosis | Office | 2023 | 21 | 23 | $13,291 | $1,628 | 12.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $3,867 | $1,446 | 37.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 266 | 664 | $199,200 | $100,812 | 50.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 194 | 538 | $134,500 | $59,583 | 44.3% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2022 | 29 | 6,000 | $120,000 | $38,805 | 32.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 50 | 413 | $82,600 | $32,033 | 38.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 94 | 297 | $48,114 | $23,342 | 48.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 309 | 1,016 | $30,480 | $7,650 | 25.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 39 | 39 | $19,110 | $7,481 | 39.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 37 | 44 | $18,920 | $6,969 | 36.8% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 35 | 39 | $15,600 | $6,258 | 40.1% |
| 85097 | Bone marrow, smear interpretation | Office | 2022 | 56 | 76 | $20,900 | $4,622 | 22.1% |
About Dr. James Mccloskey, M.D
Dr. James Mccloskey, M.D is a Hematology healthcare provider based in Hackensack, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/07/2008. The National Provider Identifier (NPI) number assigned to this provider is 1992951149.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Mccloskey, M.D has received a total of $2.8M in payments from pharmaceutical and medical device companies, with $608,974 received in 2024. These payments were reported across 2,167 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.8M).
As a Medicare-enrolled provider, Mccloskey has provided services to 5,010 Medicare beneficiaries, totaling 45,456 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology
- Location Hackensack, NJ
- Active Since 08/07/2008
- Last Updated 01/26/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1992951149
Products in Payments
- ICLUSIG (Drug) $554,828
- VYXEOS (Drug) $287,523
- Revlimid (Drug) $193,790
- AYVAKIT (Drug) $183,348
- REBLOZYL (Biological) $179,700
- ONUREG (Drug) $151,392
- BESREMI (Drug) $144,532
- OJJAARA (Drug) $141,157
- Blincyto (Biological) $132,573
- JAKAFI (Drug) $120,398
- Vonjo (Drug) $84,111
- ELZONRIS (Drug) $64,179
- Rezlidhia (Drug) $60,772
- VONJO (Drug) $59,767
- GLEEVEC (Drug) $22,769
- RYDAPT (Drug) $20,928
- TASIGNA (Drug) $18,225
- Venclexta (Drug) $16,139
- BOSULIF (Drug) $15,605
- TIBSOVO (Drug) $13,985
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Hackensack
Dr. Jamie Koprivnikar, M.d, M.D
Hematology — Payments: $1.5M
Hematology $1.5M
Dr. Andrew Pecora, Md, MD
Hematology — Payments: $1.4M
Hematology $1.4M
Dr. David Vesole, Md, MD
Hematology — Payments: $1.1M
Hematology $1.1M
Dr. Lori Leslie, M.d, M.D
Hematology — Payments: $669,511
Hematology $669,511
Dr. Robert Alter, Md, MD
Hematology — Payments: $539,884
Hematology $539,884
Dr. David Siegel, Md, MD
Hematology — Payments: $469,559
Hematology $469,559